CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Veraxa Biotech AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Veraxa Biotech AG
Talacker 35
ZUERICH, 8001  Switzerland Ticker: VRXAVRXA
Business Summary
Veraxa Biotech AG is a Switzerland-based company. The Company is primary engaged in biotechnology, advancing innovations in the field of antibody development and microfluidic technologies. The Company’s activities center on participating in and supporting businesses engaged in the screening of diagnostic and therapeutic antibodies, as well as their chemical or recombinant modification, formatting, validation, and preclinical and clinical development. In addition, the Company is involved in the commercialization and marketing of such solutions both domestically and internationally. The Company operates mainly through investments and strategic management of affiliated entities, providing services and oversight to companies within its portfolio.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6770 Blank checks
6799 Investors, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board WarrenHosseinion 51
President, Chief Executive Officer, Director AdeelRouf 32
Chief Financial Officer AlexRogers 50
3 additional Officers and Directors records available in full report.

Business Names
Business Name
VACH
VACHU
VRXA

General Information
Outstanding Shares: 147,732,813 (As of 6/8/2026)
Stock Exchange: NASD


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, June 21, 2026